NYSE:WSTLife Sciences
West Pharmaceutical Services (WST) Stock Sees Margin Improvement Narrative Backed By Q2 2026 Results
West Pharmaceutical Services (WST) has just posted Q2 2026 results with revenue of US$872.3 million, basic EPS of US$2.18 and net income of US$154 million, setting the tone for how investors assess its current profitability. The company has seen quarterly revenue move from US$766.5 million in Q2 2025 to US$872.3 million in Q2 2026, while basic EPS shifted over the same period from US$1.83 to US$2.18, giving investors a clear view of how the top line and per share earnings have tracked...